Demeetra holds the exclusive licenses for research and commercial fields in agriculture, industrial biotech and pharmaceutical bioprocessing to the platform gene editing technologies, Cas-CLOVER (the clean CRISPR/Cas9 alternative) and piggyBac transposase. We license these technologies or partner under joint development agreements for applications in the engineering of crops and agricultural animals, plant-based drug development and enhanced bioprocessing in human & animal health. Through our technology platforms, expertise and partnerships we are focused on Engineering Traits for Life.
Location: United States
Employees: 1-10
Founded date: 2019
Investors 1
| Date | Name | Website |
| - | Rapha Capi... | raphacap.c... |
Mentions in press and media 3
| Date | Title | Description |
| 18.03.2026 | Demeetra Announces Renewal of piggyBac® Technology Research License by Eisai USA - English USA - English | Demeetra AgBio, Inc. (hereafter "Demeetra") today announced that the renewal of the research license agreement for the piggyBac® transposase technology, a widely used platform for genetic engineering in research applications, by E... |
| 19.02.2026 | Demeetra Announces Renewal of Research License for piggyBac® Technology with Taiho Pharmaceutical Co., Ltd. | Demeetra AgBio, Inc. (hereafter "Demeetra") today announced that Taiho Pharmaceutical Co., Ltd. (hereinafter "Taiho") has renewed its research license agreement for the piggyBac® transposase technology, a widely used pla... |
| 11.11.2025 | Demeetra AgBio's CleanCut GS CHO Cells Achieve Dual Viral Clearance Validation, Confirming GMP-Ready Status | Dual viral clearance validation positions CleanCut GS CHO as a GMP-ready, high-productivity platform for biopharma and CDMOs. LEXINGTON, Ky., Nov. 11, 2025 /PRNewswire-PRWeb/ -- Demeetra announced today that its flagship CleanCut GS CHO cel... |